BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 36811330)

  • 1. RSV through the COVID-19 pandemic: Burden, shifting epidemiology, and implications for the future.
    Stein RT; Zar HJ
    Pediatr Pulmonol; 2023 Jun; 58(6):1631-1639. PubMed ID: 36811330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory syncytial virus, recurrent wheeze and asthma: A narrative review of pathophysiology, prevention and future directions.
    Binns E; Tuckerman J; Licciardi PV; Wurzel D
    J Paediatr Child Health; 2022 Oct; 58(10):1741-1746. PubMed ID: 36073299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory syncytial virus bronchiolitis in congenital diaphragmatic hernia: A systematic review of prevalence rates and palivizumab prophylaxis.
    Lewis L; Sinha I; Losty PD
    Pediatr Pulmonol; 2022 Jan; 57(1):239-244. PubMed ID: 34617409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease burden of respiratory syncytial virus infection in the pediatric population in Japan.
    Nagasawa K; Ishiwada N
    J Infect Chemother; 2022 Feb; 28(2):146-157. PubMed ID: 34952776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus in children: epidemiology and clinical impact post-COVID-19.
    Rice E; Oakes DB; Holland C; Moore HC; Blyth CC
    Curr Opin Infect Dis; 2023 Dec; 36(6):522-528. PubMed ID: 37830952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis.
    Cong B; Koç U; Bandeira T; Bassat Q; Bont L; Chakhunashvili G; Cohen C; Desnoyers C; Hammitt LL; Heikkinen T; Huang QS; Markić J; Mira-Iglesias A; Moyes J; Nokes DJ; Ploin D; ; Seo E; Singleton R; Wolter N; Fu Yung C; Zar HJ; Feikin DR; Sparrow EG; ; Nair H; Li Y;
    Lancet Infect Dis; 2024 Apr; 24(4):361-374. PubMed ID: 38141633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs.
    Roy Á; Polazzi S; Ploin D; Gillet Y; Javouhey E; Lina B; ; Myard-Dury AF; Couray-Targe S; Duclos A; Casalegno JS
    Vaccine; 2023 Jun; 41(25):3796-3800. PubMed ID: 37198017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Nonpharmaceutical Interventions Implemented in Response to the COVID-19 Pandemic on Seasonal Respiratory Syncytial Virus: Analysis of Google Trends Data.
    Ravkin HD; Yom-Tov E; Nesher L
    J Med Internet Res; 2022 Dec; 24(12):e42781. PubMed ID: 36476385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
    Chida-Nagai A; Sato H; Sato I; Shiraishi M; Sasaki D; Izumi G; Yamazawa H; Cho K; Manabe A; Takeda A
    Eur J Pediatr; 2022 Feb; 181(2):539-547. PubMed ID: 34417646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-2015.
    Choi SH; Park KS; Kim YJ
    J Infect Chemother; 2019 Jul; 25(7):514-519. PubMed ID: 30885457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants.
    Staebler S; Blake S
    Policy Polit Nurs Pract; 2021 Feb; 22(1):41-50. PubMed ID: 33050785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
    Resch B; Egger B; Kurath-Koller S; Urlesberger B
    Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and prevention of respiratory syncytial virus infections in children in Italy.
    Azzari C; Baraldi E; Bonanni P; Bozzola E; Coscia A; Lanari M; Manzoni P; Mazzone T; Sandri F; Checcucci Lisi G; Parisi S; Piacentini G; Mosca F
    Ital J Pediatr; 2021 Oct; 47(1):198. PubMed ID: 34600591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential impact of COVID-19 non-pharmaceutical interventions on the epidemiological dynamics of respiratory syncytial virus subtypes A and B.
    Holmdahl I; Bents SJ; Baker RE; Casalegno JS; Trovão NS; Park SW; Metcalf JE; Viboud C; Grenfell B
    Sci Rep; 2024 Jun; 14(1):14527. PubMed ID: 38914626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory Syncytial Virus Outbreaks Are Predicted after the COVID-19 Pandemic in Tokyo, Japan.
    Madaniyazi L; Seposo X; Ng CFS; Tobias A; Toizumi M; Moriuchi H; Yoshida LM; Hashizume M
    Jpn J Infect Dis; 2022 Mar; 75(2):209-211. PubMed ID: 34470964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory syncytial virus (RSV) infection in children with medical complexity.
    Lim A; Butt ML; Dix J; Elliott L; Paes B
    Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):171-176. PubMed ID: 30374685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Nonpharmaceutical Interventions during the COVID-19 Pandemic on the Prevalence of Respiratory Syncytial Virus in Hospitalized Children with Lower Respiratory Tract Infections: A Systematic Review and Meta-Analysis.
    Leija-Martínez JJ; Esparza-Miranda LA; Rivera-Alfaro G; Noyola DE
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International changes in respiratory syncytial virus (RSV) epidemiology during the COVID-19 pandemic: Association with school closures.
    Billard MN; van de Ven PM; Baraldi B; Kragten-Tabatabaie L; Bont LJ; Wildenbeest JG
    Influenza Other Respir Viruses; 2022 Sep; 16(5):926-936. PubMed ID: 35733362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
    Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
    Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL;
    Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.